September 5, 2024 | 10:30pm
September 5, 2024 | 10:30pm
September 5, 2024 | 10:30pm
October 1, 2024 | 10:30pm
The political turmoil in Bangladesh has created significant obstacles for Indian pharmaceutical exporters and medical tourism companies. Pharma companies are struggling with issues such as blocked payments, misplaced shipments, and unresponsive importers. Meanwhile, Indian medical tourism is also suffering as patients from the region are either abruptly cancelling their plans or are unable to travel due to the local unrest.
According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), an arm that functions under the Ministry of Commerce and Industry, now Indian companies are hesitant to supply products to Bangladesh due to unpaid dues and concerns about financial stability.
“Due to the political unrest in Bangladesh, the Indian Pharmaceutical industry — which is into export of drugs and intermediates — has been facing significant challenges, including unpaid dues, concerns about the financial stability and logistics issues,” Raja Bhanu, director general of Pharmexcil, told News18.
Also, Bhanu highlighted that due to shared borders, logistics become a major issue, with shipments getting stuck at the border and difficulties in securing insurance but now the conditions are mildly improving.
“In Bangladesh, we may expect the political and economic scenario to improve. However, it is too early to make a conclusive statement on how it will affect our sector,” Bhanu said.
Reflecting a noticeable exposure, Bangladesh sources 30 per cent of its pharmaceutical ingredients from India, which is served by big pharmaceutical firms as well as small and medium-sized firms.
The government data shows that exports to Bangladesh fluctuated in financial year 2024-25 with a decline in activity in June. After a 42.48 per cent increase from April to May, exports grew modestly by 5.66 per cent in June, indicating a slowdown in growth momentum despite earlier gains.
News18 reached out to several drug makers for a comment. However, either they did not respond to the e-mails or they requested anonymous comments.
Sun Pharma has significant exposure to the country as the drug maker has a full-fledged drug manufacturing site and commercial operation which began in 2004. However, the company did not respond to an email sent by News18.
Another Mumbai-based drug maker who exports to Bangladesh told News18 requesting anonymity that the company has stopped taking new export orders until normalcy resumes.
“While the condition is better now in terms of movement of shipments, we still haven’t been able to find out lost shipments costing several lakhs that went missing during the clashes. We are not taking any fresh export orders for Bangladesh till the situation goes back to normal.”
Note: MediJourn does not offer medical advice, diagnoses, or treatment. The information and services provided on medijourn.com are for informational purposes only and are not a substitute for professional consultation or treatment by a physician. MediJourn strongly discourages the copying or cloning of its webpages and content and will take legal action to protect its intellectual property.